CMN 572 TESTS COMPILATION BUNDLE
2026 EXAM SCRIPT FULL QUESTIONS AND
VERIFIED ANSWERS PREMIUM RESOURCE
GRADED A+
⩥ Management of Genital Warts in Immunodeficient Patients.
Answer: More frequent occurance, resistance to treatment, atypical
lesions r/t immunodeficiency
Treatment unlikely to be effective due to high recurrence rate; therefore,
treat only if the patient is symptomatic.
⩥ re-occurrence of genital warts protocol:.
Answer: Up to 2/3 of patients will experience recurrences of warts
within 6-12 weeks of therapy; after 6 months most patients have
clearance.
If persistent after 3 months, or if there is poor response to treatment or
hyperpigmented lesions, consider biopsy to exclude a premalignant or
neoplastic condition, especially in an immunocompromised person.
Treatment modality should be changed if patient has not improved
substantially after 3 provider-administered treatments or if warts do not
completely clear after 6 treatments.
,⩥ Pap Test Screening in Immunodeficient Patients.
Answer: Immunodeficiency appears to accelerate intraepithelial
neoplasia and invasive cancer
Provide cervical Pap test screening every 6 months for 1 year, then
annually for all HIV-infected women with or without genital warts
⩥ Genital Wart Follow-Up.
Answer: Counsel patients to:
Watch for recurrences
Get regular Pap screening at intervals as recommended for women
WITHOUT genital warts
After visible warts have cleared, follow-up evaluation not mandatory,
but provides opportunity to:
Monitor or treat complications of therapy
Document the absence of warts
Reinforce patient education and counseling messages
Offer patients concerned about recurrences a follow-up evaluation 3
months after treatment.
,Primary goal is removal of symptomatic warts.
No evidence that presence of genital warts or their treatment is
associated with development of cervical cancer
⩥ Partner Management & Risk reduction of HPV.
Answer: Abstinence and long-term mutual monogamy with an
uninfected partner are the most effective options to prevent transmission.
HPV infections can occur in male and female genital areas that are not
covered by a latex condom, as well as in areas that are covered
Likelihood of transmission and duration of infectivity with or without
treatment are unknown.
Sex partner examination is not necessary
⩥ What is Pelvic Inflammatory Disease (PID)?.
Answer: ascending spread of microorganisms from the vagina or cervix
to the endometrium, fallopian tubes, ovaries, and contiguous structures.
⩥ risk factors associated with PID.
Answer: Adolescence
Gonorrhea or chlamydia, or a history of
Male partners with gonorrhea or chlamydia
, Multiple partners
Current douching
Insertion of IUD
Bacterial vaginosis
Oral contraceptive use (in some cases)
Demographics (socioeconomic status)
⩥ most common pathogens causing PID:.
Answer: Neisseria gonorrhea and chlamydia trachomatis
⩥ Minimum Criteria in the Diagnosis of PID.
Answer: Uterine tenderness, or
Adnexal tenderness, or
Cervical motion tenderness
⩥ Additional Diagnostic Criteria to Increase Specificity of PID
Diagnosis.
Answer: Temperature >38.3°C (101°F)
Abnormal cervical or vaginal mucopurulent discharge
Presence of abundant numbers of WBCs on saline microscopy of
vaginal secretions
2026 EXAM SCRIPT FULL QUESTIONS AND
VERIFIED ANSWERS PREMIUM RESOURCE
GRADED A+
⩥ Management of Genital Warts in Immunodeficient Patients.
Answer: More frequent occurance, resistance to treatment, atypical
lesions r/t immunodeficiency
Treatment unlikely to be effective due to high recurrence rate; therefore,
treat only if the patient is symptomatic.
⩥ re-occurrence of genital warts protocol:.
Answer: Up to 2/3 of patients will experience recurrences of warts
within 6-12 weeks of therapy; after 6 months most patients have
clearance.
If persistent after 3 months, or if there is poor response to treatment or
hyperpigmented lesions, consider biopsy to exclude a premalignant or
neoplastic condition, especially in an immunocompromised person.
Treatment modality should be changed if patient has not improved
substantially after 3 provider-administered treatments or if warts do not
completely clear after 6 treatments.
,⩥ Pap Test Screening in Immunodeficient Patients.
Answer: Immunodeficiency appears to accelerate intraepithelial
neoplasia and invasive cancer
Provide cervical Pap test screening every 6 months for 1 year, then
annually for all HIV-infected women with or without genital warts
⩥ Genital Wart Follow-Up.
Answer: Counsel patients to:
Watch for recurrences
Get regular Pap screening at intervals as recommended for women
WITHOUT genital warts
After visible warts have cleared, follow-up evaluation not mandatory,
but provides opportunity to:
Monitor or treat complications of therapy
Document the absence of warts
Reinforce patient education and counseling messages
Offer patients concerned about recurrences a follow-up evaluation 3
months after treatment.
,Primary goal is removal of symptomatic warts.
No evidence that presence of genital warts or their treatment is
associated with development of cervical cancer
⩥ Partner Management & Risk reduction of HPV.
Answer: Abstinence and long-term mutual monogamy with an
uninfected partner are the most effective options to prevent transmission.
HPV infections can occur in male and female genital areas that are not
covered by a latex condom, as well as in areas that are covered
Likelihood of transmission and duration of infectivity with or without
treatment are unknown.
Sex partner examination is not necessary
⩥ What is Pelvic Inflammatory Disease (PID)?.
Answer: ascending spread of microorganisms from the vagina or cervix
to the endometrium, fallopian tubes, ovaries, and contiguous structures.
⩥ risk factors associated with PID.
Answer: Adolescence
Gonorrhea or chlamydia, or a history of
Male partners with gonorrhea or chlamydia
, Multiple partners
Current douching
Insertion of IUD
Bacterial vaginosis
Oral contraceptive use (in some cases)
Demographics (socioeconomic status)
⩥ most common pathogens causing PID:.
Answer: Neisseria gonorrhea and chlamydia trachomatis
⩥ Minimum Criteria in the Diagnosis of PID.
Answer: Uterine tenderness, or
Adnexal tenderness, or
Cervical motion tenderness
⩥ Additional Diagnostic Criteria to Increase Specificity of PID
Diagnosis.
Answer: Temperature >38.3°C (101°F)
Abnormal cervical or vaginal mucopurulent discharge
Presence of abundant numbers of WBCs on saline microscopy of
vaginal secretions
